Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
The purpose of this study is to find out how much tratuzumab deruxtecan (T-DXd) can penetrate the tumor when injected into the body, and whether T-DXd may be an effective treatment for brain cancers that express the HER2 protein.
Brain Cancer|Glioblastoma|Metastatic Cancer|Leptomeningeal Metastasis|Recurrent Glioblastoma
DRUG: Trastuzumab deruxtecan
Intraoperative plasma concentrations in brain tumors after T-DXd injections, To evaluate the brain tumor penetration of trastuzumab deruxtecan (T-DXd) and its payload (DXd) in Her2+/Her2-low/Her2-mutant brain metastases and of Her2-expressing glioblastoma. Concentrations will be presented as brain tumor:plasma ratios across brain lesions, using intraoperative plasma concentrations, Up to 24 months
The purpose of this study is to find out how much tratuzumab deruxtecan (T-DXd) can penetrate the tumor when injected into the body, and whether T-DXd may be an effective treatment for brain cancers that express the HER2 protein.